Sugi Predict

Sugi Predict / Compounds / SCHEMBL6061185

SCHEMBL6061185

SCHEMBL6061185

CCCCCCCCCCCOS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RECQL P46063 2/20 0.50
▸ GLA P06280 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ TSHR P16473 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ EPHX2 P34913 1/20 0.50
▸ MCHR1 Q99705 1/20 0.50
▸ BLM P54132 1/20 0.50
▸ CA1 P00915 10/20 0.47
▸ CA2 P00918 10/20 0.47
▸ CA9 Q16790 9/20 0.47
▸ CA12 O43570 4/20 0.47
▸ CA7 P43166 3/20 0.47
▸ CA14 Q9ULX7 3/20 0.47
▸ CA3 P07451 2/20 0.47
▸ CA4 P22748 2/20 0.47
▸ CA6 P23280 2/20 0.47
▸ CA5A P35218 2/20 0.47
▸ CA5B Q9Y2D0 2/20 0.47
▸ PLA2G2C Q5R387 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL345885 1.00 RECQL (0.50) RECQLGLAHPGDTSHRMAPK1
SCHEMBL5015857 1.00 RECQL (0.50) RECQLGLAHPGDTSHRMAPK1
SCHEMBL8085071 1.00 RECQL (0.50) RECQLGLAHPGDTSHRMAPK1
SCHEMBL4193998 1.00 RECQL (0.50) RECQLGLAHPGDTSHRMAPK1
SCHEMBL2194649 1.00 RECQL (0.50) RECQLGLAHPGDTSHRMAPK1
SCHEMBL10731635 1.00 RECQL (0.50) RECQLGLAHPGDTSHRMAPK1
SCHEMBL974536 1.00 RECQL (0.50) RECQLGLAHPGDTSHRMAPK1
SCHEMBL10725263 1.00 RECQL (0.50) RECQLGLAHPGDTSHRMAPK1
SCHEMBL3088278 1.00 RECQL (0.50) RECQLGLAHPGDTSHRMAPK1
SCHEMBL812482 1.00 RECQL (0.50) RECQLGLAHPGDTSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122056281-A Application of indoleamide compound as linker for mediating interaction of ubiquitin ligase and effector protein 中国农业大学 2026-05-19 — — CN disclosed
CN-120058698-A Azetidine and pyrrolidine PARP1 inhibitors and uses thereof 新特拉有限公司 2025-05-30 — — CN disclosed
CN-118019532-B Azetidine and pyrrolidine PARP1 inhibitors and uses thereof 新特拉有限公司 2025-03-18 — — CN disclosed
CN-118019532-A Azetidine and pyrrolidine PARP1 inhibitors and uses thereof 新特拉有限公司 2024-05-10 — — CN disclosed
EP-4334307-A1 CDK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-03-13 — — EP disclosed
CN-117651698-A Pyridone MK2 inhibitors and uses thereof 新特拉有限公司 2024-03-05 — — CN disclosed
CN-112638477-B Pyrrolo [2,3-B ] pyridine derivatives as inhibitors of influenza virus replication 共晶制药公司 2024-01-26 — — CN disclosed
WO-2024018762-A1 PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLE 国立大学法人北海道大学 2024-01-25 — — WO disclosed
CN-117177972-A PARP1 inhibitors and uses thereof 新特拉有限公司 2023-12-05 — — CN disclosed
CN-117120430-A MK2 inhibitors and uses thereof 新特拉有限公司 2023-11-24 — — CN disclosed
CN-110637022-A Pyrrolopyrimidine derivatives as inhibitors of influenza virus replication 共晶制药公司 2019-12-31 — — CN disclosed
CN-102459268-A Diazahomoadamantane derivatives and methods of use thereof ABBOTT LAB 2012-05-16 — — CN disclosed
EP-1678115-A2 PROCESS FOR PREPARING FUNCTIONAL GROUP-CONTAINING OLEFINIC COMPOUNDS 3M Innovative Properties Company (US) 2006-07-12 — — EP disclosed
US-6951963-B2 Process for preparing N-protected β-amino aldehyde compounds THERAVANCE, INC. (US) 2005-10-04 — — US disclosed
WO-2005042462-A2 PROCESS FOR PREPARING FUNCTIONAL GROUP-CONTAINING OLEFINIC COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-05-12 — — WO disclosed
US-20030233010-A1 Process for perparing N-protected beta-amino aldehyde compounds CUMBERLAND PHARMACEUTICALS INC. 2003-12-18 — — US disclosed
EP-0758013-B1 Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display NIPPON OIL CO LTD (JP) 2000-10-11 — — EP disclosed
US-5855971-A Liquid crystalline optical film, compensating film for liquid crystal display comprising the liquid crystalline optical film, and liquid crystal display having the compensating film NIPPON OIL COMPANY, LIMITED (JP) 1999-01-05 — — US disclosed
EP-0758013-A1 Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display NIPPON OIL COMPANY, LIMITED (JP) 1997-02-12 — — EP disclosed
EP-0012622-B1 1-TOSLOXY-2,2-ETHYLENEDIOXY-6,10-DIMETHYL UNDECANES AND UNDECENES, PROCESS FOR THE PREPARATION OF 2S*,3R*-3-BENZYLOXY-6,6-ETHYLENE DIOXY-2-METHYL-2-(5'-HYDROXY-4'-METHYLPENTYL)-OXEPANE, AND USE OF THE LATTER FOR THE PREPARATION OF OXEPAN-3-OL DERIVATIVES ORTHO PHARMACEUTICAL CORPORATION (US) 1982-12-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030233010-A1 Process for perparing N-protected beta-amino aldehyde compounds DNPEP, PREP, ANPEP RECQL 4852/4885GLA 172/4885HPGD 1463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.